WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit

MT Newswires Live01-15

WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.

Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.

The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.

BioDlink said it had formed an independent board committee to advise shareholders on the offer.

Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.

Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.

The company expects to post its financial results by March 23.

WuXi XDC is controlled by WuXi Biologics (HKG:2269).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603622754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 11:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603622754","market":"nz","top_or_hot":-1,"title":"WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit","media":"MT Newswires Live","content":"<html><body><p> WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.</p><p>Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.</p><p>The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.</p><p>BioDlink said it had formed an independent board committee to advise shareholders on the offer.</p><p>Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.</p><p>Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.</p><p>The company expects to post its financial results by March 23.</p><p>WuXi XDC is controlled by WuXi Biologics (HKG:2269).</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi XDC Launches Takeover Offer for BioDlink International, Forecasts Rise in 2025 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-15 11:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.</p><p>Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.</p><p>The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.</p><p>BioDlink said it had formed an independent board committee to advise shareholders on the offer.</p><p>Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.</p><p>Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.</p><p>The company expects to post its financial results by March 23.</p><p>WuXi XDC is controlled by WuXi Biologics (HKG:2269).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516423174.USD","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603622754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603622754","pubTimestamp":1768447295,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.Shares of the contract research, development and man","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1574":"生物医药B类股","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","01875":"东曜药业-B","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK1521":"挪威政府全球养老基金持仓","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","02269":"药明生物","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0051755006.USD":"摩根大通中国A (dist)","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","BK1589":"北水核心资产","LU1720050803.USD":"安联全方位中国股票基金","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","BK1141":"生命科学工具和服务","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK1576":"医药外包概念","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1610":"ETF&股票定投概念","BK1161":"生物科技","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","02268":"药明合联","LU3063872942.SGD":"FULLERTON LUX FUNDS ASIA EQUITIES \"I\" (SGD) ACC","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC"},"translate_title":"无锡XDC向BioDlink International发起收购要约，预计2025年利润将增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1,"02269":1,"02268":1},"content_text":"WuXi XDC (HKG:2268) made an offer to acquire BioDlink International (HKG:1875) for HK$4 per share in cash, according to a joint statement Wednesday.Shares of the contract research, development and manufacturing organization fell nearly 3% in morning trade Thursday, while BioDlink jumped nearly 69%.The offer represents a maximum consideration of HK$2.79 billion for the business. WuXi XDC plans to retain BioDlink's Hong Kong listing after the acquisition.BioDlink said it had formed an independent board committee to advise shareholders on the offer.Meanwhile, WuXi XDC said it expects its net profit for 2025 to rise by at least 38% year-on-year. The firm posted 1.07 billion yuan in profit attributable to owners for 2024.Revenue for the year is expected to rise at least 45% when compared to the 4.05 billion yuan posted in 2024.The company expects to post its financial results by March 23.WuXi XDC is controlled by WuXi Biologics (HKG:2269).","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603622754","isCrawlerRequest":true}